Martin Louis Wilson - 11 Feb 2026 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Reporting relationship: General Counsel
Issuer ticker: RCKT
Reported as of: 11 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Feb 2026, 16:05:24 UTC
Prior SEC filing: 20 Nov 2025
Next SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Martin Louis Wilson

Key filing fact

Martin Louis Wilson filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 13 Feb 2026.

Key facts

This page summarizes Martin Louis Wilson's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Feb 2026, 16:05.

Change

Previous filing in this sequence was filed on 20 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001704342 Primary reporting owner

Wilson Martin

Relationship: General Counsel
Address: C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY
Signature: /s/ Martin Louis Wilson
Signature date: 13 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCKT transaction

Common Stock

Award

Transaction value: $0
Shares: +311,813
Change %: +81%
Price: $0.000000
Shares after: 695,629
Date: 11 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +468,187
Change %
Price: $0.000000
Shares after: 468,187
Date: 11 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 468,187
Exercise price: $3.24
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Footnote F2

Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.

Footnote F3

This option represents a right to purchase a total of 468,187 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.